INT315817

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.42
First Reported 2009
Last Reported 2010
Negated 0
Speculated 1
Reported most in Body
Documents 2
Total Number 2
Disease Relevance 0.67
Pain Relevance 0.09

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (RRM1) nucleoplasm (RRM1) small molecule metabolic process (RRM1)
oxidoreductase activity (RRM1) cytoplasm (RRM1)
RRM1 (Homo sapiens)
Pain Link Frequency Relevance Heat
palliative 1 94.40 High High
withdrawal 2 5.00 Very Low Very Low Very Low
tolerance 1 5.00 Very Low Very Low Very Low
anesthesia 1 5.00 Very Low Very Low Very Low
ischemia 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Non-small-cell Lung Cancer 35 97.68 Very High Very High Very High
Toxicity 22 90.92 High High
Pancreatic Cancer 3 75.84 Quite High
Cancer 10 70.48 Quite High
Disease 5 60.00 Quite High
Lung Cancer 6 5.00 Very Low Very Low Very Low
Cv Unclassified Under Development 3 5.00 Very Low Very Low Very Low
Respiratory Failure 2 5.00 Very Low Very Low Very Low
Metastasis 2 5.00 Very Low Very Low Very Low
Death 2 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Being a major target of gemcitabine, RR has been widely investigated in cohorts of NSCLC patients treated with the drug, with specific attention for the RRM1 subunit.76–79 Most of the studies showed that RRM1 mRNA expression was associated with significantly longer overall survival in patients who received a gemcitabine-based doublet both in the neoadjuvant and palliative setting,76–79 while it represented a prognostic factor for decreased survival for patients who underwent surgery alone.80 In addition, also RRM1 polymorphisms have been correlated with outcome in NSCLC patients treated with gemcitabine,81 despite the lack of a clear association between different haplotypes and RRM1 expression.81,82 These findings led investigators to perform a randomized phase II trial aimed at customizing treatment based on ERCC1 – a predictor for platinum compounds activity83 – and RRM1 expression in 85 chemonaive NSCLC patients with advanced disease84 Based on tumor expression of these two biomarkers, doublets including carboplatin, gemcitabine, vinorelbine and docetaxel were selected.
Transcription (expression) of RRM1 associated with cancer, non-small-cell lung cancer and palliative
1) Confidence 0.42 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886326 Disease Relevance 0.67 Pain Relevance 0.09
A similar analysis was followed to determine the optimum sampling frequency of the RR(n) and TTot(n) series, considering ? 
Spec (determine) Transcription (frequency) of RR
2) Confidence 0.40 Published 2010 Journal Ann Biomed Eng Section Body Doc Link PMC2900596 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox